Peptide Database/Semaglutide

MetabolicFDA Approved

Semaglutide

Semaglutide (GLP-1 agonist)

Add to protocol

Build with Semaglutide

Compare prices

Pharmacies & vendors

Calculate dosing

Reconstitution

Overview

Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes management and chronic weight management. It mimics the incretin hormone GLP-1 to regulate appetite and glucose metabolism.

Mechanism of Action

Binds to and activates GLP-1 receptors, leading to enhanced insulin secretion, reduced glucagon secretion, delayed gastric emptying, and reduced appetite through central nervous system effects.

Research Summary

The STEP clinical trial program demonstrated average weight loss of 15–17% body weight over 68 weeks. The SELECT trial showed a 20% reduction in major adverse cardiovascular events. Oral semaglutide (Rybelsus) is also FDA-approved for type 2 diabetes.

Dosing Information

Typical Dose

0.25-2.4mg

Range

0.25-2.4mg (titrated)

Frequency

1x/week (subcutaneous)

Route

SubQ or Oral

Duration

12+ weeks (ongoing)

Reconstitution

Pre-filled pen or compounded vial

Notes

SubQ dosing follows a titration schedule: 0.25 mg for 4 weeks, then 0.5 mg, escalating to target dose. Oral form must be taken on an empty stomach with no more than 4 oz of water.

Reported Side Effects

Nausea and vomiting
Diarrhea or constipation
Abdominal pain
Injection site reactions
Potential pancreatitis (rare)
Gallbladder issues

Contraindications

Personal or family history of medullary thyroid carcinoma
Multiple endocrine neoplasia syndrome type 2 (MEN 2)
History of pancreatitis
Pregnancy or breastfeeding

Labs to monitor before & during your Semaglutide protocol

These biomarkers are commonly tracked to assess response and safety. Run baseline labs before starting, mid-cycle labs halfway through, and post-cycle labs 1–2 weeks after the final dose.

HbA1cFasting glucoseInsulinLipid panelCRPLiver enzymes

Order blood work

Commonly Stacked With

Tirzepatide Mots-C

Research References

Wilding JPH, et al. New England Journal of Medicine. 2021;384(11):989-1002.
Marso SP, et al. New England Journal of Medicine. 2016;375(19):1834-1844.

Track your Semaglutide protocol

Build a protocol with Semaglutide, schedule blood work for key biomarkers, and track your results.

Build Protocol with Semaglutide

This platform provides informational tools only, not medical advice. This information is for educational purposes only. Consult a licensed provider.

Dosing Information

Typical Dose

0.25-2.4mg

Range

0.25-2.4mg (titrated)

Frequency

1x/week (subcutaneous)

Route

SubQ or Oral

Duration

12+ weeks (ongoing)

Reconstitution

Pre-filled pen or compounded vial

Notes

SubQ dosing follows a titration schedule: 0.25 mg for 4 weeks, then 0.5 mg, escalating to target dose. Oral form must be taken on an empty stomach with no more than 4 oz of water.